IRONWOOD PHARMACEUTICALS, INC. Restructuring Charges
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Restructuring Charges of $20.65 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2023-12-31 was $639.00K.
- IRONWOOD PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2023-09-30 was $4.70M.
- IRONWOOD PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2021-12-31 was $1.12M, a 92.12% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. restructuring charges for the quarter ending 2021-09-30 was -$73.00K, a 105.93% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. restructuring charges for fiscal 2025 was $20.65M, a 690.58% increase from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. restructuring charges for fiscal 2024 was $2.61M, a 85.03% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. restructuring charges for fiscal 2023 was $17.44M.
- IRONWOOD PHARMACEUTICALS, INC. restructuring charges for fiscal 2021 was $1.07M, a 93.03% decline from fiscal 2020.
| Period end | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 6 month as first filed | Restructuring Charges 9 month | Restructuring Charges 9 month as first filed | Restructuring Charges 12 month | Restructuring Charges 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $20.65M 10-K · filed 2026-02-26 | |||||||
| 2024-12-31 | $2.61M 10-K · filed 2026-02-26 | |||||||
| 2023-12-31 | $639.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $5.34M derived: sum of 2 quarters · filed 2025-03-31 | $17.44M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $4.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $16.80M 10-Q · filed 2023-11-09 | ||||||
| 2023-06-30 | $12.10M 10-Q · filed 2023-08-09 | |||||||
| 2021-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $1.04M derived: sum of 2 quarters · filed 2023-02-16 | $762.00K derived: sum of 3 quarters · filed 2023-02-16 | $1.07M 10-K · filed 2023-02-16 | ||||
| 2021-09-30 | -$73.00K 10-Q · filed 2021-11-04 | -$355.00K derived: sum of 2 quarters · filed 2021-11-04 | -$44.00K 10-Q · filed 2021-11-04 | $14.12M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2021-06-30 | -$282.00K 10-Q · filed 2021-08-05 | $29.00K 10-Q · filed 2021-08-05 | $14.20M derived: sum of 3 quarters · filed 2022-02-18 | $15.43M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2021-03-31 | $311.00K 10-Q · filed 2021-05-06 | $14.48M derived: sum of 2 quarters · filed 2022-02-18 | $15.71M derived: sum of 3 quarters · filed 2022-02-18 | |||||
| 2020-12-31 | $14.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $15.40M derived: sum of 2 quarters · filed 2022-02-18 | $15.40M 10-K · filed 2022-02-18 | $15.38M 10-K · filed 2021-02-17 | ||||
| 2020-09-30 | $1.23M 10-Q · filed 2021-11-04 | $1.23M 10-Q · filed 2021-11-04 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | -$52.00K derived: sum of 2 quarters · filed 2022-02-18 | -$218.00K derived: sum of 3 quarters · filed 2022-02-18 | $272.00K derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | -$52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$218.00K derived: sum of 2 quarters · filed 2022-02-18 | $272.00K derived: sum of 3 quarters · filed 2022-02-18 | $3.60M 10-K · filed 2022-02-18 | $3.62M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | -$166.00K 10-Q · filed 2019-10-31 | $324.00K derived: sum of 2 quarters · filed 2020-08-06 | $3.65M 10-Q · filed 2019-10-31 | $4.36M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-06-30 | $490.00K 10-Q · filed 2020-08-06 | $3.82M 10-Q · filed 2020-08-06 | $4.52M derived: sum of 3 quarters · filed 2021-02-17 | $14.63M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-03-31 | $3.33M 10-Q · filed 2020-05-06 | $4.03M derived: sum of 2 quarters · filed 2021-02-17 | $14.13M derived: sum of 3 quarters · filed 2021-02-17 | $15.62M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2018-12-31 | $705.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $10.81M derived: sum of 2 quarters · filed 2021-02-17 | $12.29M derived: sum of 3 quarters · filed 2021-02-17 | $14.71M 10-K · filed 2021-02-17 | $15.88M 10-K · filed 2019-02-25 | |||
| 2018-09-30 | $10.10M 10-Q · filed 2019-10-31 | $10.28M 10-Q · filed 2018-11-06 | $11.59M derived: sum of 2 quarters · filed 2019-10-31 | $14.01M 10-Q · filed 2019-10-31 | $15.10M 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $1.49M 10-Q · filed 2019-07-30 | $2.39M 10-Q · filed 2018-08-06 | $3.91M 10-Q · filed 2019-07-30 | $4.81M 10-Q · filed 2018-08-06 | ||||
| 2018-03-31 | $2.42M 10-Q · filed 2019-05-02 | |||||||
| 2014-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | $1.10M derived: sum of 2 quarters · filed 2015-02-18 | $551.00K 10-K · filed 2015-02-18 | |||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | -$551.00K 10-Q · filed 2014-11-05 | ||||||
| 2014-06-30 | -$551.00K 10-Q · filed 2014-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |